Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 18/20 | 0.55 |
| ▸ | PPARA | Q07869 | 17/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413103 | 0.92 | KDR (0.55) | FFAR1KDRPPARGPPARA | |
| SCHEMBL5399220 | 0.92 | FFAR1 (0.69) | FFAR1PPARGPPARA | |
| SCHEMBL4845660 | 0.86 | FFAR1 (0.54) | FFAR1PPARGPPARA | |
| SCHEMBL12652902 | 0.84 | FFAR1 (0.78) | FFAR1KDRPPARGPPARACYP2C9 | |
| SCHEMBL5403539 | 0.84 | FFAR1 (0.57) | FFAR1KDRPPARGPPARA | |
| SCHEMBL4034751 | 0.82 | FFAR1 (0.81) | FFAR1KDRPPARGPPARACYP2C9 | |
| SCHEMBL4031039 | 0.80 | KDR (0.74) | FFAR1KDRPPARGPPARACYP2C9 | |
| SCHEMBL5404374 | 0.79 | FFAR1 (0.46) | FFAR1PPARGPPARA | |
| SCHEMBL1744988 | 0.78 | FFAR1 (0.64) | FFAR1KDRPPARGPPARACYP2C9 | |
| SCHEMBL4032802 | 0.78 | FFAR1 (0.64) | FFAR1KDRPPARGPPARACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | claimed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | claimed |
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | FFAR1 14/4885KDR 2417/4885PPARG 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.